【BIOHLDG 0179 交流专区】

icy97

科鼎業績如何？

2015-10-04 19:25      

讀者tay問：
今年初上市的科鼎控股（BIOHLDG，0179，創業板消費品組）業績如何，是否有上升空間？記得公司執行董事韓丁國說過，今年將會研發更多產品及年中將把業務發展到中東，進展如何呢？是否值得買入？

答：
截至2015年6月30日為止第二季，科鼎控股取得淨利39萬6千令吉（每股淨利為0.09仙），前期淨利為179萬9千令吉（每股淨利為0.50仙）。營業額為825萬2千令吉，前期為812萬6千令吉。

首6個月淨利跌至41萬令吉（每股淨利為0.10仙），前期為161萬5千令吉（每股淨利為0.44仙）。首6個月營業額為1千147萬9千令吉，前期為1千零69萬5千令吉。

該公司第二季淨利較少，主要是包括上市開支218萬1千令吉所致，若是不包括上市開支，該公司盈利表現較前期佳。

該公司營收表現良好，主要是旗下草藥產品成功打入中國市場，即中國市場在次季取得229萬1千令吉的營業額。該公司每股資產值為15.67仙。

該公司在宣佈次季業績，談到公司未來業務展望時指出，該公司已經完成清理龍運巴西拉惹的123.5英畝的土地，以便開始種植藥草，預料今年杪即可以開始收割。

該公司將會積極地向中國市場推展公司的保健輔助產品，主要是通過參與主要省份的展覽會進行推介促銷活動。

5月14日，MyAngkasa投資在公司子公司-Alphacare，為後者現有的“Life Springs”零售分店進行執照安排至逾1萬間注冊的合作社及逾800萬名的合作社會員。

8月18日，該公司與方正（PUC，0007，創業板科技組）簽署一項備忘錄，為雙方土地互相使用而鋪路，即該公司負責種植藥草，而方正則在土地上建設它的太陽能設施。

根據翻查資料所得，並沒有關於該公司研究更多新產品及把業務發展到中東的消息，所以沒有新的進展。是否值得買進，至今沒有證券行進行剖析及給予任何投資建議。（星洲日報／投資致富‧投資問診‧文：李文龍）

icy97

Name	MR HON TIAN KOK @ WILLIAM
Address	No 52A, Jalan 8/35A Taman Seri Bangi Seksyen 8 Bandar Baru Bangi 43650 Selangor Malaysia.
NRIC/Passport No/Company No.	761203016683
Nationality/Country of incorporation	Malaysia
Descriptions (Class & nominal value)	Ordinary shares of RM0.05 each
Name & address of registered holder	HON TIAN KOK @ WILLIAMNo 52A, Jalan 8/35A Taman Seri Bangi Seksyen 843650 Bandar Baru BangiSelangor Darul Ehsan

Details of changes

Currency: Malaysian Ringgit (MYR)

Type of transaction	Description of Others	Date of change	No of securities	Price Transacted (RM)
Disposed		19 Oct 2015	12,000,000	0.290
Disposed		21 Oct 2015	9,000,000	0.290
Disposed		22 Oct 2015	1,000,000	0.290

Circumstances by reason of which change has occurred	Disposal of shares via direct business transaction
Nature of interest	Direct Interest
Direct (units)	100,303,560
Direct (%)	21.64
Indirect/deemed interest (units)	0
Indirect/deemed interest (%)	0
Total no of securities after change	100,303,560
Date of notice	22 Oct 2015

icy97

Name	MR HON TIAN KOK @ WILLIAM
Address	No 52A, Jalan 8/35A Taman Seri Bangi Seksyen 8 Bandar Baru Bangi 43650 Selangor Malaysia.
NRIC/Passport No/Company No.	761203016683
Nationality/Country of incorporation	Malaysia
Descriptions (Class & nominal value)	Ordinary shares of RM0.05 each
Name & address of registered holder	HON TIAN KOK @ WILLIAMNo 52A, Jalan 8/35A Taman Seri Bangi Seksyen 843650 Bandar Baru BangiSelangor Darul Ehsan

Details of changes

Currency: Malaysian Ringgit (MYR)

Type of transaction	Description of Others	Date of change	No of securities	Price Transacted (RM)
Disposed		28 Oct 2015	10,000,000	0.290

Circumstances by reason of which change has occurred	Disposal of shares via off market transaction
Nature of interest	Direct Interest
Direct (units)	81,473,560
Direct (%)	17.58
Indirect/deemed interest (units)	0
Indirect/deemed interest (%)	0
Total no of securities after change	81,473,560
Date of notice	29 Oct 2015

icy97

BIOALPHA HOLDINGS BERHAD

Particulars of substantial Securities Holder

Name	PERBADANAN NASIONAL BERHAD
Address	Level 11, Menara PNS Tower 7 Avenue 7, Bangsar South City No. 8, Jalan Kerinchi Kuala Lumpur 59200 Wilayah Persekutuan Malaysia.
NRIC/Passport No/Company No.	9157-K
Nationality/Country of incorporation	Malaysia
Descriptions (Class & nominal value)	Ordinary shares of RM0.05 each
Name & address of registered holder	Perbadanan Nasional Berhad Level 11, Menara PNS Tower 7 Avenue 7, Bangsar South CityNo. 8, Jalan Kerinchi59200 Kuala LumpurWilayah Persekutuan

Details of changes

Currency: Malaysian Ringgit (MYR)

Type of transaction	Description of Others	Date of change	No of securities	Price Transacted (RM)
Disposed		29 Oct 2015	28,055,157	0.250

Circumstances by reason of which change has occurred	Disposal of shares via off market transaction
Nature of interest	Direct Interest
Direct (units)	77,331,920
Direct (%)	16.69
Indirect/deemed interest (units)	0
Indirect/deemed interest (%)	0
Total no of securities after change	77,331,920
Date of notice	30 Oct 2015

icy97

Name	MR HON TIAN KOK @ WILLIAM
Address	No 52A, Jalan 8/35A Taman Seri Bangi Seksyen 8 Bandar Baru Bangi 43650 Selangor Malaysia.
NRIC/Passport No/Company No.	761203016683
Nationality/Country of incorporation	Malaysia
Descriptions (Class & nominal value)	Ordinary shares of RM0.05 each
Name & address of registered holder	HON TIAN KOK @ WILLIAMNo 52A, Jalan 8/35A Taman Seri Bangi Seksyen 843650 Bandar Baru BangiSelangor Darul Ehsan

Details of changes

Currency: Malaysian Ringgit (MYR)

Type of transaction	Description of Others	Date of change	No of securities	Price Transacted (RM)
Acquired		29 Oct 2015	20,055,157	0.250

Circumstances by reason of which change has occurred	Acquisition of shares via off market transaction
Nature of interest	Direct Interest
Direct (units)	101,528,717
Direct (%)	21.91
Indirect/deemed interest (units)	0
Indirect/deemed interest (%)	0
Total no of securities after change	101,528,717
Date of notice	30 Oct 2015

icy97

Name	MR HON TIAN KOK @ WILLIAM
Address	No 52A, Jalan 8/35A Taman Seri Bangi Seksyen 8 Bandar Baru Bangi 43650 Selangor Malaysia.
NRIC/Passport No/Company No.	761203016683
Nationality/Country of incorporation	Malaysia
Descriptions (Class & nominal value)	Ordinary shares of RM0.05 each
Name & address of registered holder	HON TIAN KOK @ WILLIAMNo 52A, Jalan 8/35A Taman Seri Bangi Seksyen 843650 Bandar Baru BangiSelangor Darul Ehsan

Details of changes

Currency: Malaysian Ringgit (MYR)

Type of transaction	Description of Others	Date of change	No of securities	Price Transacted (RM)
Disposed		02 Nov 2015	10,000,000	0.300

Circumstances by reason of which change has occurred	Disposal of shares via off market transaction
Nature of interest	Direct Interest
Direct (units)	86,528,717
Direct (%)	18.67
Indirect/deemed interest (units)	0
Indirect/deemed interest (%)	0
Total no of securities after change	86,528,717
Date of notice	03 Nov 2015

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Sep 2015

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Sep 2015	30 Sep 2014	30 Sep 2015	30 Sep 2014
		$$'000	$$'000	$$'000	$$'000

1	Revenue	8,536	8,069	20,015	18,765
2	Profit/(loss) before tax	2,534	1,906	3,048	4,088
3	Profit/(loss) for the period	2,441	2,073	2,638	3,734
4	Profit/(loss) attributable to ordinary equity holders of the parent	2,552	2,216	2,963	3,831
5	Basic earnings/(loss) per share (Subunit)	0.55	0.61	0.70	0.11
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1625		0.1494

icy97

EX-date	10 Dec 2015
Entitlement date	14 Dec 2015
Entitlement time	05:00 PM
Entitlement subject	First Interim Dividend
Entitlement description	First Interim Single Tier Dividend of RM0.0009 per share for the financial year ending 31 December 2015
Period of interest payment	to
Financial Year End	31 Dec 2015
Share transfer book & register of members will be	to   closed from (both dates inclusive) for the purpose of determining the entitlement
Registrar or Service Provider name, address, telephone no	SYMPHONY SHARE REGISTRARS SDN BHDLevel 6, Symphony HousePusat Dagangan Dana 1Jalan PJU 1A/4647301Petaling JayaTel:0378490777Fax:0378418151
Payment date	08 Jan 2016
a.Securities transferred into the Depositor's Securities Account before 4:00 pm in respect of transfers	14 Dec 2015
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit
c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)
Entitlement indicator	Currency
Currency	Malaysian Ringgit (MYR)
Entitlement in Currency	0.0009
Par Value	Malaysian Ringgit (MYR) 0.050

icy97

发股筹469.5万 科鼎500万购Mediconstant

财经新闻 财经  2015-12-19 12:30
（吉隆坡18日讯）科鼎（BIOHLDG，0179，创业板消费股）宣布，将通过发股方式，以总值500万令吉收购Mediconstant控股。

根据日前的文告，公司将发行1886万7924股进行上述收购计划，每股发售价为26.5仙。

一旦完成收购之后，Mediconstant将会成为科鼎的独资子公司。

Mediconstant涉及的业务包括药剂行，以及提供管理和资讯服务。

此外，科鼎也建议，配售高达1771万8962股新股，或占缴足资本接近3.82%比重。

假设每股配售价为26.5仙，预计能够筹得469万5000令吉，主要是为Mediconstant购买货物，包括药物、保健品，以及个人护理产品。

大马卫生部已调整数项重大政策，推动保健领域增长。

在看好国内保健领域将在经济增长中扮演着有力的引擎，科鼎因而决定收购Mediconstant。【南洋网财经】

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	BIOALPHA HOLDINGS BERHAD ("BIOALPHA" OR "COMPANY")PROPOSED ACQUISITION OF THE ENTIRE EQUITY INTEREST IN MEDICONSTANT HOLDING SDN BHD (MEDICONSTANT) FOR A PURCHASE CONSIDERATION OF RM5,000,000 (PROPOSED ACQUISITION)
The Board of Directors of Bioalpha (“Board”) wishes to announce that Botanical Distribution Sdn Bhd (“Purchaser” or “BDSB”), a wholly-owned subsidiary of Bioalpha, had on 16 December 2015 entered into a term sheet (“Term Sheet”) with Ng See Hein and Loh Peng Yeow (collectively referred to as the “Vendors”) for the acquisition of the entire equity interest in Mediconstant comprising 50,000 ordinary shares of RM1.00 each in Mediconstant (“Mediconstant Shares”) (“Sale Shares”) for a purchase consideration of RM5,000,000 (“Purchase Consideration”). The details of the Proposed Acquisition are set out in the attachment herein. This announcement is dated 16 December 2015.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/4952701

Attachments Bioalpha- Proposed Acquisition - Final.pdf

icy97

Type	Announcement
Subject	NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS) FUND RAISING
Description	BIOALPHA HOLDINGS BERHAD ("BIOALPHA" OR THE "COMPANY")PROPOSED PRIVATE PLACEMENT OF UP TO 17,718,962 NEW ORDINARY SHARES OF RM0.05 EACH IN BIOALPHA ("BIOALPHA SHARES") REPRESENTING 3.82% OF THE EXISTING ISSUED AND PAID-UP SHARE CAPITAL OF BIOALPHA ("PROPOSED PRIVATE PLACEMENT")
On behalf of the Board of Directors of Bioalpha (“Board”), TA Securities Holdings Berhad (“TA Securities”) wishes to announce that the Company proposes to undertake the Proposed Private Placement. Please refer to the attachment below for further details of the announcement. This announcement is dated 16 December 2015.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/4952697

Attachments Announcement - (only 132D) - final.pdf

icy97

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	BIOALPHA HOLDINGS BERHAD (BIOALPHA OR COMPANY)PROPOSED ACQUISITION OF THE ENTIRE EQUITY INTEREST IN MEDICONSTANT HOLDING SDN BHD (MEDICONSTANT) FOR A PURCHASE CONSIDERATION OF RM5,000,000 (PROPOSED ACQUISITION)
Further to the Company's announcement made on 16 December 2015. The Board wishes to announce that Botanical Distribution Sdn. Bhd. ("BDSB"), a wholly-owned subsidiary of the Company had on 18 December 2015 entered into a sale of shares agreement (“SSA”) with Ng See Hein and Loh Peng Yeow for the Proposed Acquisition. The details of the SSA are set out in the attachment herein. This announcement is dated 18 December 2015.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/4955261

Attachments Bioalpha - SSA (final).pdf

icy97

BIOALPHA HOLDINGS BERHAD

1. Details of Corporate Proposal
Involve issuance of new type/class of securities ?	No
Types of corporate proposal	Private Placement
Details of corporate proposal	Acquisition of the entire equity interest in Mediconstant Holding Sdn Bhd ("Mediconstant") comprising 50,000 ordinary shares of RM1.00 each in Mediconstant for a purchase consideration of RM5,000,000 to be fully satisfied through the issuance of 18,867,924 ordinary shares of RM0.05 each in Bioalpha Holdings Berhad ("Bioalpha") ("Bioalpha Shares") representing approximately 4.07% of the existing issued and paid-up share capital of Bioalpha ("Acquisition")
No. of shares issued under this corporate proposal	18,867,924
Issue price per share ($$)	Malaysian Ringgit (MYR)   0.0500
Par Value ($$)	Malaysian Ringgit (MYR)   0.050
Latest issued and paid up share capital after the above corporate proposal in the following
Units	482,281,038
Currency	Malaysian Ringgit (MYR) 24,114,051.900
Listing Date	21 Jan 2016

icy97

Type	Announcement
Subject	NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS) FUND RAISING
Description	BIOALPHA HOLDINGS BERHAD ("BIOALPHA" OR THE "COMPANY")PRIVATE PLACEMENT OF UP TO 17,718,962 NEW ORDINARY SHARES OF RM0.05 EACH IN BIOALPHA ("BIOALPHA SHARES") REPRESENTING 3.82% OF THE ISSUED AND PAID-UP SHARE CAPITAL OF BIOALPHA ("PRIVATE PLACEMENT")
We refer to the announcements made on 16 December 2015, 21 December 2015 and 13 January 2016 in relation to the Private Placement (“Announcements”). Unless otherwise defined, the definitions set out in the Announcements shall apply herein. On behalf of Bioalpha, TA Securities wishes to announce that the Board has on 29 January 2016 fixed the issue price for the placement of 17,718,962 Placement Shares at RM0.330 per Placement Share (“Issue Price”). The Issue Price represents a discount of RM0.0002 or approximately 0.06% over the five (5)-day volume weighted average market price of the Bioalpha Shares up to and including 28 January 2016 of RM0.3302. This announcement is dated 29 January 2016.

icy97

買進券商心頭好．聯營有助擴大市場 科鼎盈利前景樂觀
  
2016年2月05日

券商：聯昌證券研究
目標價：65仙

我們看好科鼎（BIOHLDG，0179，創業板消費）與MyAngkasa的合作，可為公司帶來巨大潛能，未來數年的盈利前景樂觀，維持“增持”投資評級。

由于MyAngkasa旗下有1萬2000個合作社和800萬會員，我們相信，科鼎與MyAngkasa組聯營，設立零售與藥房分店，可讓公司銷售更多自家品牌的產品，長期將有利公司。

尤其作為綜合草藥補品供應商，科鼎將近60%營業額來自自家品牌的貢獻。

科鼎將在今年展開這項聯營，相信可為公司帶來巨大發展潛能。

另外，我們相信，中國將成為該公司今年主要市場之一。中國消費者在去年次季才開始購買該公司的產品，相信這市場可持續成長，進而帶動銷售表現。

基于未來幾年的強勁盈利成長前景，我們維持該股“增持”評級，根據2017年19.8倍本益比，給予目標價65仙。【中国报财经】

icy97

BIOALPHA HOLDINGS BERHAD

1. Details of Corporate Proposal
Involve issuance of new type/class of securities ?	No
Types of corporate proposal	Private Placement
Details of corporate proposal	Private placement of up to 17,718,962 new ordinary shares of RM0.05 each in Bioalpha ("Bioalpha Shares") representing 3.67% of the existing issued and paid-up share capital of Bioalpha ("Private Placement")
No. of shares issued under this corporate proposal	17,718,962
Issue price per share ($$)	Malaysian Ringgit (MYR)   0.3300
Par Value ($$)	Malaysian Ringgit (MYR)   0.050
Latest issued and paid up share capital after the above corporate proposal in the following
Units	500,000,000
Currency	Malaysian Ringgit (MYR) 25,000,000.000
Listing Date	12 Feb 2016

icy97

現金多業務前景俏 科鼎尚有97%揚升空間
  
2016年2月15日
（吉隆坡15日訊）隨著科鼎（BIOHLDG，0179，創業板消費）完成私下配售，不但有助鞏固現金地位，亦可增設更多新藥妝店，拓展業務，潛在上揚空間高達97%。

該公司私下配售1770萬股新股，集得580萬令吉料供在全國開設新藥妝店。
　
聯昌證券研究指出，科鼎截至去年9月底淨現金達1510萬令吉，加上私下配售所得現金流將增至2090萬令吉，相等于每股4仙。至于集得580萬令吉金額，估計將用以開設新藥妝店。

該公司與MyAngkasa偕手成立聯營合作，分別持有70%和30%股權，以在國內開設更多零售和藥妝店。

該行估計開設一間藥妝店平均需要100萬令吉，科鼎在收購Constant藥妝集團后，在巴生谷共持有13間藥妝店。公司管理層指將在有意開設自家藥妝店的合作社尋求股權參與，並可提供經營藥妝店的管理專才。

另外，科鼎可在自家藥妝店推廣自己的品牌，目前貢獻公司60%營業額。該公司在過去曾將自家品牌置入其他藥妝店銷售，但收費昂貴且科鼎要在眾多品牌和產品突圍甚為艱難。

聯昌證券研究維持科鼎每股盈利預測，並給于65仙目標價，距離目前股價水平尚有97%揚升空間，投資評級為“增持”。【中国报财经】


科鼎 私配所得增门市
财经 股市 行家论股  2016-02-16 12:19
http://www.nanyang.com/node/748339?tid=462

icy97

icy97 发表于 20-8-2015 03:33 PM

科鼎方正中止 土地共享协议

财经新闻 财经  2016-02-19 15:22
（吉隆坡18日讯）科鼎（BIOHLDG，0179，创业板消费股）宣布，中止早前与方正（PUC，0007，创业板）签署的备忘录。

去年8月19日，双方签署了解备忘录，以探讨共享土地使用权的可能。

不过，经过可行性研究后双方发现，从商业角度来看，共享土地使用权已不再可行。

因此，科鼎今天宣布，双方已同意中止早前的备忘录，即日起生效。

根据早前的协议，科鼎计划在方正所属的土地上，进行草药种植，而方正也打算在科鼎的种植土地上，建造以及经营太阳能光伏发电。【南洋网财经】

Type	Announcement
Subject	MEMORANDUM OF UNDERSTANDING
Description	BIOALPHA HOLDINGS BERHAD (BIOALPHA OR COMPANY)TERMINATION OF MEMORANDUM OF UNDERSTANDING (MOU) BETWEEN BIOALPHA AND PUC FOUNDER (MSC) BERHAD (PUCF)
Reference is made to the Company’s announcement dated 19 August 2015 in relation to the Memorandum of Understanding (“MOU”) between Bioalpha Holdings Berhad (“Bioalpha” or “Company”) and PUC Founder (MSC) Berhad (“PUCF”). The Board of Directors of Bioalpha wishes to announce that the MOU entered into between the Company and PUCF in relation to the Land Rights Sharing is no longer commercially viable subsequent to the feasibility study conducted. In view of the above, the Company and PUCF has mutually agreed in writing to terminate the MOU with effect from 16 February 2016. This announcement is dated 16 February 2016.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Dec 2015

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Dec 2015	31 Dec 2014	31 Dec 2015	31 Dec 2014
		$$'000	$$'000	$$'000	$$'000

1	Revenue	9,705	8,350	29,720	27,115
2	Profit/(loss) before tax	4,254	2,698	7,302	6,786
3	Profit/(loss) for the period	3,817	2,563	6,455	6,297
4	Profit/(loss) attributable to ordinary equity holders of the parent	3,831	2,601	6,794	6,432
5	Basic earnings/(loss) per share (Subunit)	0.83	0.72	1.56	1.77
6	Proposed/Declared dividend per share (Subunit)	0.01	0.13	0.01	0.13
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1699		0.1494

icy97

科鼎 新产品料热销

财经 股市 行家论股  2016-03-01 13:15

目标价：65仙

最新进展
科鼎（BIOHLDG，0179，创业板消费股）2015财年营业额，年增9.6%；但净利却仅小增6.3%。

若排除240万令吉的上市开支，净利则年增46%，至920万令吉。

行家建议
冬虫夏草和东革阿里（Tongkat Ali）是科鼎最畅销的产品，贡献营业额50%。

不过，过去几年，公司积极推销新的菇种虎奶菇（Tiger Milk Mushroom），这是一种主要在东盟区域找到的菇类，传统是用在呼吸系统疾病上，特别是哮喘，相信以后能成为科鼎的最热销产品。

此外，最大的财源来自印尼业务，贡献近半营业额；接下来中国的势力不容小觑，已经以28%的销售占比，成为科鼎的第二大市场，有望在1至2年内就成为最大市场。

中东也有潜力成为科鼎的庞大市场，正与阿联酋的Fathima集团合作，在海湾国家分销产品。

对于与MyAngkasa联营，在全国成立零售和药房的计划，预计在第二季开始营运，将可让公司卖出更多自家品牌。

我们维持2016至2018财年的财测和评级，目标价是根据2017年19.8倍本益比计算，较我们所设的目标溢价20%。中国的和MyAngkasa联营的新利好消息，将可激励估值上调。



分析：肯纳格研究

【南洋网财经】

icy97

進軍電子商務獲看好 Bioalpha控股受追捧
  
2016年3月10日
（吉隆坡10日訊）Bioalpha控股（BIOHLDG，0179，創業板消費）將于本月涉足電子商務領域，同時，與MyAngkasa的聯營前景獲券商看好，帶動該股交投十分活絡。

Bioalpha控股與MyAngkasa聯營，將在全國范圍內開涉保健品零售和制藥據點，並專營基礎下營運，由Constant藥妝集團管理。該聯營的優勢在于MyAngkasa的800萬名會員，他們可向合作社購買該公司產品，故此聯營預計將推動Bioalpha控股的國內銷售。

同時，Bioalpha控股將于本月通過Constant藥妝集團網站推出電子商務業務。

聯昌證券研究指出：“目前，購買Bioalpha控股產品的唯一方法是通過Constant藥妝主要分布在巴生谷的店鋪。電子商務業務推出后，巴生谷以外，甚至海外都能買到該公司產品。”

另外，該公司超過90%的出口銷售均以令吉計價。因此外匯波動將不會影響其獲利能力。該研究相信，當業務版圖擴大后，Bioalpha控股可在不久的將來以國際貨幣為其產品定價，如美元。

基于該公司優于預期的中國和印尼銷售成績，及與MyAngkasa聯營的發展動向，聯昌證券研究維持該公司“增持”評級，目標價65仙。【中国报财经】